Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 68,202	$ 35,371	$ 11,144
General and administrative	18,865	5,256	2,498
Total operating expenses	87,067	40,627	13,642
Loss from operations	(87,067)	(40,627)	(13,642)
Other income (expense):
Change in fair value of preferred stock tranche liability	0	2,507	(4,883)
Change in fair value of antidilution rights liability	(25,574)	(5,359)	(982)
Change in fair value of success payment liability	(7,815)	(2,387)	(68)
Interest and other income, net	142	162	278
Total other expense, net	(33,247)	(5,077)	(5,655)
Net loss	$ (120,314)	$ (45,704)	$ (19,297)
Net loss per common share attributable to common stockholders, basic and diluted	$ (4.48)	$ (20.31)	$ (15.11)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted	26,872,036	2,250,093	1,277,156
Comprehensive Loss:
Net loss	$ (120,314)	$ (45,704)	$ (19,297)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(236)	(1)	9
Comprehensive loss	$ (120,550)	$ (45,705)	$ (19,288)